摘要
目的分析新生儿感染性肺炎(NIP)行静注人免疫球蛋白(pH4)联合注射用头孢哌酮钠舒巴坦钠治疗的临床效果。方法选取138例NIP患儿,以随机数字表法分为对照组和观察组,各69例。对照组给予注射用头孢哌酮钠舒巴坦钠治疗,观察组在对照组基础上加用静注人免疫球蛋白(pH4)治疗。对比两组疗效、症状缓解时间、免疫功能指标、炎症因子指标、不良反应发生情况。结果观察组总有效率95.65%高于对照组的75.36%(P<0.05)。观察组肺啰音消失时间、喘息消失时间、咳嗽消失时间、呼吸困难缓解时间、体温稳定时间分别为(5.05±0.49)、(2.15±0.24)、(5.06±0.82)、(2.81±0.28)、(2.42±0.32)d,均短于对照组的(6.47±0.78)、(3.08±0.38)、(7.11±1.23)、(3.54±0.43)、(3.46±0.43)d(P<0.05)。治疗后,观察组CD4^(+)、CD4^(+)/CD8^(+)、免疫球蛋白G(IgG)、IgG1、IgG2、IgG3水平均高于对照组,CD8^(+)水平低于对照组(P<0.05)。治疗后,观察组白细胞介素-6(IL-6)、降钙素原(PCT)、C反应蛋白(CRP)水平均低于对照组(P<0.05)。两组不良反应发生率对比无明显差异(P>0.05)。结论NIP治疗时选择注射用头孢哌酮钠舒巴坦钠联合静注人免疫球蛋白(pH4)疗效显著,且具较高安全性,可采纳。
Objective To analyze the clinical effect of human intravenous immunoglobulin(pH4)combined with cefoperazone sodium and sulbactam sodium for injection in the treatment of neonatal infectious pneumonia(NIP).Methods 138 cases of NIP children were selected and divided into control group and observation group by random numerical table,with 69 cases in each group.The control group was given cefoperazone sodium and sulbactam sodium for injection,and the observation group was given human immunoglobulin(pH4)based on the control group.The efficacy,symptom remission time and immune function index,inflammatory markers,and occurrence of adverse reactions of the two groups were compared.Results The total effective rate of 95.65%in the observation group was higher than 75.36%in the control group(P<0.05).In the observation group,the disappearance time of pulmonary rales,the disappearance time of wheezing,the disappearance time of cough,the relief time of dyspnea and temperature stabilization time were(5.05±0.49),(2.15±0.24),(5.06±0.82),(2.81±0.28)and(2.42±0.32)d,which were shorter than(6.47±0.78),(3.08±0.38),(7.11±1.23),(3.54±0.43)and(3.46±0.43)d in the control group(P<0.05).After treatment,CD4+,CD4+/CD8+,immunoglobulin G(IgG),IgG1,IgG2 and IgG3 in the observation group were higher than those in the control group,and CD8+was lower than that in the control group(P<0.05).After treatment,the interleukin-6(IL-6),procalcitonin(PCT)and C-reactive protein(CRP)in the observation group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The use of cefoperazone sodium and sulbactam sodium for injection combined with human intravenous immunoglobulin(pH4)in the treatment of NIP has significant therapeutic effects and high safety,and can be adopted.
作者
刘鉴达
LIU Jian-da(Shenyang Maternity and Infant Hospital,Shenyang 110011,China)
出处
《中国现代药物应用》
2025年第11期109-112,共4页
Chinese Journal of Modern Drug Application
关键词
新生儿感染性肺炎
静注人免疫球蛋白(pH4)
注射用头孢哌酮钠舒巴坦钠
炎症因子
Neonatal infectious pneumonia
Human intravenous immunoglobulin(pH4)
Cefoperazone sodium and sulbactam sodium for injection
Inflammatory factors
